US FDA panels urges more study on paediatric antipsychotic use
This article was originally published in SRA
Executive Summary
A US Food and Drug Administration advisory panel on 22 September voted 16-1 in favour of the agency routinely monitoring the safety of new antipsychotics used to treat children, specifically examining ways to highlight in labelling the risks of weight gain and diabetes associated with the medications1.